Pfizer on Tuesday hailed a study of a weight-loss-drug candidate while forecasting a profit decline due to the impact of the Trump administration’s policies on pricing and tariffs.
Pfizer study finds patients lose up to 12% of their weight after taking once-a-month drug
Related Posts
Popular News
Latest News
Galaxy posts $482 million net loss in Q4 2025, shares drop 13%
Galaxy Digital (GLXY) stock fell 13% on Tuesday morning after the company disclosed a $482 million net loss for Q4...
The Nintendo Switch 2 Can Handle AAA Games Better Than People Think
When the Nintendo Switch 2 came out, I was a bit skeptical that such a thin and light device could...
Cathie Wood Scoops Crypto Stocks BMNR, CRCL, BLSH, and HOOD in Recent Fall
Key NotesThe recent purchase of crypto stocks came across different Ark Invest portfolio ETFs.Although ARK’s ETFs remained under pressure following...
How much Trump accounts could grow, according to financial experts
U.S. President Donald Trump points a finger onstage at the U.S. Treasury Department's Trump Accounts Summit, in Washington, D.C., U.S....
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.